Solving protein structures, and specifically protein structures bound to ligands that are your potential drug candidates are very, very early phases in drug development. That is before even the phase 1 trials.

It's important work and a significant effort, but it's not where the actual difficulty in drug development lies. 90% of drugs fail after that point, and that is where you need to get better if you want to beat the current approaches.

AI also can't run drug trials faster than humans. They take a lot of time, effort and money.